AR041764A1 - Vacuna basada en polinucleotidos y proteinas derivados del vih - Google Patents
Vacuna basada en polinucleotidos y proteinas derivados del vihInfo
- Publication number
- AR041764A1 AR041764A1 ARP030104033A ARP030104033A AR041764A1 AR 041764 A1 AR041764 A1 AR 041764A1 AR P030104033 A ARP030104033 A AR P030104033A AR P030104033 A ARP030104033 A AR P030104033A AR 041764 A1 AR041764 A1 AR 041764A1
- Authority
- AR
- Argentina
- Prior art keywords
- hiv
- protein
- pharmaceutical composition
- additional
- composition according
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 238000011238 DNA vaccination Methods 0.000 abstract 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000011324 bead Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract 1
- 239000010931 gold Substances 0.000 abstract 1
- 229910052737 gold Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a polinucleótidos para la vacunación con ADN, polinucleótidos que codifican una proteína de la cubierta del VIH o fragmento o derivado inmunógeno, que no está glicosilada cuando se expresa en una célula diana de mamífero, ligada de forma operable a un promotor heterólogo. Preferiblemente la molécula de la cubierta del VIH, tal como gp120 o gp140 o gp160, carece de una senal de secreción funcional. Puede estar fusionada a proteínas adicionales del VIH tales como Nef, Gag, RT o Tat. Reivindicación 25: Una proteína de fusión que comprende una proteína de la cubierta del VIH sustancialmente no glicosilada o un fragmento o derivado inmunógeno de la misma y al menos una proteína adicional del VIH o un fragmento derivado inmunógeno de la misma, seleccionándose dicha proteína adicional del VIH de Nef, Gag, RT y Tat. Reivindicación 28: Una composición farmacéutica que comprende una secuencia nucleótida o un conjunto de secuencias nucleotídicas de acuerdo con una cualquiera de las reivindicaciones 1 a 20, un vector de las reivindicaciones 21 a 24, una proteína de fusión de acuerdo con la reivindicación 25 o una composición de acuerdo con la reivindicación 26 o un polipéptido de acuerdo con la reivindicación 27, y un excipiente, diluyente, vehículo o adyuvante farmacéuticamente aceptable. Reivindicación 29: La composición farmacéutica de acuerdo con la reivindicación 28 en la que el vehículo es una pluralidad de partículas tales como perlas de oro. Reivindicación 31: Un dispositivo de administración intradérmica que comprende una composición farmacéutica de acuerdo con una cualquiera de las reivindicaciones 28 a 30.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0225788.9A GB0225788D0 (en) | 2002-11-05 | 2002-11-05 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041764A1 true AR041764A1 (es) | 2005-05-26 |
Family
ID=9947247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104033A AR041764A1 (es) | 2002-11-05 | 2003-11-04 | Vacuna basada en polinucleotidos y proteinas derivados del vih |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7655235B2 (es) |
| EP (1) | EP1558636A2 (es) |
| JP (1) | JP2006520185A (es) |
| AR (1) | AR041764A1 (es) |
| AU (1) | AU2003301850A1 (es) |
| CA (1) | CA2505209A1 (es) |
| GB (1) | GB0225788D0 (es) |
| TW (1) | TW200418873A (es) |
| WO (1) | WO2004041852A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0225788D0 (en) | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| KR101451620B1 (ko) * | 2005-05-12 | 2014-10-21 | 글락소 그룹 리미티드 | 백신 조성물 |
| WO2007071997A2 (en) * | 2005-12-21 | 2007-06-28 | Glaxo Group Limited | Method of eliciting immune response |
| TWI477602B (zh) * | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
| AU2007275047A1 (en) | 2006-07-20 | 2008-01-24 | University Of Washington | Compositions and methods for vaccinating against HSV-2 |
| CN101675068A (zh) * | 2007-03-02 | 2010-03-17 | 葛兰素史密丝克莱恩生物有限公司 | 新的方法和组合物 |
| US8569065B2 (en) * | 2009-03-13 | 2013-10-29 | Egen, Inc. | Compositions and methods for the delivery of biologically active RNAs |
| CA2807616A1 (en) | 2010-08-09 | 2012-02-16 | Richard Markham | Methods and compositions for preventing a condition |
| WO2012040101A1 (en) | 2010-09-21 | 2012-03-29 | University Of Miami | Compositions and methods for inducing migration by dendritic cells and an immune response |
| WO2012040266A2 (en) * | 2010-09-24 | 2012-03-29 | University Of Miami | Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines |
| MA40783A (fr) * | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| KR20230131481A (ko) | 2021-01-14 | 2023-09-13 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신 및 이의 사용 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0172970B1 (ko) | 1992-06-17 | 1999-02-01 | 김영길 | Aids백신에 유용한 키메릭 단백 및 그의 제조방법 |
| WO1995032000A1 (en) * | 1994-05-20 | 1995-11-30 | Microgenesys, Inc. | Hiv polyprotein immunogens |
| WO1998041536A1 (en) | 1997-03-14 | 1998-09-24 | President And Fellows Of Harvard College | Glycosylation deficient siv and hiv envelope glycoproteins |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| AU1023401A (en) | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| WO2001047955A2 (en) | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
| CN1326873C (zh) * | 2000-01-31 | 2007-07-18 | 史密丝克莱恩比彻姆生物有限公司 | 用于hiv预防或治疗性免疫的疫苗 |
| CN1635876A (zh) * | 2000-02-04 | 2005-07-06 | 杜克大学 | 人免疫缺陷病毒疫苗 |
| GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
| EP2065468A1 (en) * | 2000-08-14 | 2009-06-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Modifications of hiv env enhance immunogenicity for genetic immunization |
| CA2389275A1 (en) | 2000-09-06 | 2002-03-14 | Stephen M. Mathis | Music assisted therapy |
| CU23235A1 (es) | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| MXPA04002631A (es) | 2001-09-20 | 2004-07-08 | Glaxo Group Ltd | Vacunas de adn optimizadas por codon gag-vih. |
| US20030190308A1 (en) | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| GB0225788D0 (en) | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
-
2002
- 2002-11-05 GB GBGB0225788.9A patent/GB0225788D0/en not_active Ceased
-
2003
- 2003-11-03 US US10/533,734 patent/US7655235B2/en not_active Expired - Fee Related
- 2003-11-03 EP EP03810446A patent/EP1558636A2/en not_active Withdrawn
- 2003-11-03 CA CA002505209A patent/CA2505209A1/en not_active Abandoned
- 2003-11-03 AU AU2003301850A patent/AU2003301850A1/en not_active Abandoned
- 2003-11-03 WO PCT/EP2003/012402 patent/WO2004041852A2/en not_active Ceased
- 2003-11-03 TW TW092130709A patent/TW200418873A/zh unknown
- 2003-11-03 JP JP2004549136A patent/JP2006520185A/ja active Pending
- 2003-11-04 AR ARP030104033A patent/AR041764A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004041852A2 (en) | 2004-05-21 |
| JP2006520185A (ja) | 2006-09-07 |
| WO2004041852A3 (en) | 2004-06-24 |
| US7655235B2 (en) | 2010-02-02 |
| TW200418873A (en) | 2004-10-01 |
| US20070042977A1 (en) | 2007-02-22 |
| EP1558636A2 (en) | 2005-08-03 |
| AU2003301850A8 (en) | 2004-06-07 |
| CA2505209A1 (en) | 2004-05-21 |
| AU2003301850A1 (en) | 2004-06-07 |
| GB0225788D0 (en) | 2002-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041764A1 (es) | Vacuna basada en polinucleotidos y proteinas derivados del vih | |
| VanCott et al. | Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160 | |
| JP5543921B2 (ja) | 免疫応答をモジュレートするための発現系 | |
| AU2007202739B2 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| CN100387617C (zh) | Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法 | |
| EP0677111B1 (en) | Novel proteinaceous particles | |
| AR041765A1 (es) | Vacuna a dna para la profilaxis y el tratamiento de infeccion por hiv | |
| JP2013501038A5 (es) | ||
| Boots et al. | Localization of a T-cell epitope within the nucleocapsid protein of avian coronavirus | |
| JP2019520058A5 (es) | ||
| CN111358943A (zh) | 一种新冠病毒的双靶向免疫增强型多价疫苗及其制备方法 | |
| EP2237794A2 (en) | Chimeric hiv fusion proteins as vaccines | |
| Scandella et al. | Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development | |
| ES2296793T3 (es) | Peptidos de vih de regiones conservadas, tat, rev y wef y su aplicacion como por ejemplo componentes de vacuna. | |
| EP0298633A2 (en) | Synthetic polypeptides | |
| US20220380412A1 (en) | Compositions comprising v2 opt hiv envelopes | |
| BR9204851A (pt) | Antigeno de HIV e processo para sua produçao molécula de DNA recombinante, reagente para diagnóstico e vacina para sindrome da imunodeficiência adquirida | |
| Girard et al. | Progress in the development of HIV vaccines | |
| ES2079493T3 (es) | Proteina de membrana externa p1 y peptidos haemophilus influenzae tipo b. | |
| EP4305057A1 (en) | Hiv-1 envelope glycopeptide nanoparticles and their uses | |
| CA3234955A1 (en) | Compositions comprising v2 opt hiv envelopes | |
| US20180036400A1 (en) | Double engineered hiv-1 envelopes | |
| Barnett et al. | Single amino acid residues in a synthetic peptide of influenza haemagglutinin, HA 1 177-199, distinguish I-Ad-and I-Ed-restricted T-cell epitopes | |
| GB0325011D0 (en) | HIV pharmaccines | |
| EP4608844A1 (en) | Compositions comprising engineered envelopes to engage cd4 binding site broadly neutralizing antibody precursors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |